Community/Retail

Alex Mills, PharmD, BCACP, AAHIVP, discussed his presentation at the ASHP 2023 Summer Meeting.

STRONG-HF aimed to study whether rapid-dose escalation of guideline-directed heart failure medications was more beneficial than usual care.

Investigators of the study aimed to determine whether the analytical performance specifications of 24,25(OH)2D could be generated.

As the OTC market has grown, Pharmacy Times has responded by adding new health sections and new OTC products to the survey.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

Myths, fears, distrust, and misinformation on immunizations can keep patients from benefiting from their protective effects.

The CDC has recommended a follow-up nucleic acid amplification test to be used for patients clinically suspected to have influenza, despite a negative POC test.

April Gill, chief commercial officer at Tabula Rasa HealthCare, discusses how to identify underserved patients and address social determinants of health.

People with less severe symptoms of insomnia still had a 16% increased risk of stroke compared to people with no symptoms.

Positive data from the phase 3 A DUE study demonstrated that the investigational combination therapy of macitentan 10 mg and tadalafil 40 in a single tablet improved pulmonary hemodynamics compared to the same drugs as monotherapies.

Christina Madison speaks with Sandra Leal, PharmD, fromCVS Health, about advocating for patients and how that impacts public health.

It’s time for pharmacies to take a page out of the books of hospitals and tech companies by expanding and streamlining their use of contingent labor.

Having more severe sleep apneas was associated with having lower brain volume in the medial temporal lobe area of the brain, which could suggest loss of brain cells.

Previously, upadacitinib improved symptoms through 2 years in the SELECT-PsA 1 trial for those with psoriatic arthritis with prior inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug.

There may be more than 200 symptoms associated with long COVID-19.

Levels of troponin were higher in people who had type 2 diabetes for a longer period than people with healthy blood levels.

CCR5 mutation creates a challenge for HIV to infect more cells, thereby creating resistance to the virus.

The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.

It’s imperative to redefine the future of pharmacy to help ensure a robust pipeline of future pharmacists and create a culture that helps ensure pharmacists live their purpose and passion.

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.

Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.

Research shows receipt of medications for chronic conditions was relatively stable in the first 2 years of the pandemic from 2020 to 2021 across racial and ethnic groups.

The primary medication therapies that can help with prophylaxis against HIV include pre-exposure prophylaxis and non-occupational post-exposure prophylaxis.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.